Business Wire

Price f(x) Files Petitions with US Patent and Trademark Office to Invalidate Vendavo’s Patents and Launches a Counter Lawsuit

Share

Price f(x), the global leader in cloud pricing software, has filed petitions for “Covered Business Method (“CBM”) Review” of four Vendavo patents, and will imminently file a fifth, which together will cover challenges to all of the patent claims that Vendavo has asserted in litigation between the parties. In Price f(x)’s view, each of Vendavo’s patents qualifies for the specialized CBM procedure created by US Congress to “crackdown on low-quality business method patents.”

Price f(x)’s petitions challenge Vendavo’s patents on a variety of grounds, including in all cases that the claims are directed to patent-ineligible abstract ideas (e.g., math for pricing of products), and in many cases that Vendavo simply tried to claim more than it actually invented. The petitions are now pending in the U.S. Patent Office, which should make an initial ruling on Price f(x)’s petitions in approximately six months. Price f(x) is concurrently moving to stay the patent portion of the parties’ litigation on the grounds that it would be wasteful to continue when the Patent Office may simply invalidate all the patents.

In December 2017, Vendavo launched a baseless lawsuit against Price f(x) thus culminating a string of hostile acts, intended to slow down Price f(x)’s dynamic growth and global expansion. Price f(x) has been initially focusing on a more cost-effective strategy of dismissing all the allegations in the early stage of the litigation. Having exhausted the options for an early end, the Company decided to intensify its defense strategy. As part of that, Price f(x) filed a countersuit on November 5th in the United States District Court for the Northern District of California, for spying, stealing and misappropriating Price f(x)’s trade secrets. The lawsuit is now pending its first Court hearing in January 2019.

Marcin Cichon, Price f(x) CEO and co-founder, noted, “we have been very disappointed with Vendavo’s baseless and hostile allegations. While we would have preferred to win in the marketplace, where our nimble, flexible, differentiated and value-adding solution has won and will continue to win, we have been forced to fight back in the courtroom. We owe it to our loyal customers, partners, employees, and investors to vigorously defend our innocence.”

About Price f(x)

Established in 2011 in Germany, Price f(x) AG is the provider of a full suite of price management and CPQ SaaS solution based on latest native cloud architecture, offering broad and flexible support to the entire price management closed loop cycle of Price Strategy, Controlling, Setting and Realization. The solution is suitable for B2B and B2C as well as for any industry, any size of business and geographical location. Price f(x)’s vision is to remain the leading SaaS pricing and CPQ platform provider through offering easy to use, fast to implement, flexible to adapt, risk free and inexpensive, comprehensive solutions. Price f(x)’s business model is entirely based on the satisfaction and loyalty of its customers. For more information please visit: www.pricefx.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Price f(x)
Marcin Cichon CEO
+49 (0) 180 5-7742339
info@pricefx.eu

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

IonQ Unanimously Appoints Peter Chapman as Next Chairman of the Board of Directors26.4.2024 13:30:00 CEST | Press release

IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ’s upcoming Annual General Meeting on June 5, 2024. Both appointments were disclosed in a proxy statement issued on April 25, 2024. Peter Chapman has also been nominated for re-election as a Class III director at the meeting, and his chairmanship will take effect assuming he is re-elected. “Last quarter we were delighted to have appointed Robert Cardillo and Bill Scannell to our Board of Directors. In addition, the Board unanimously appointed Peter Chapman to serve as its next Chairman following the annual meeting given his half-decade worth of contributions to IonQ and his strong progress transitioning IonQ from an academic to a commercial company,” said Niccolo de Masi, Chairman of the Nominating & Corporate Governance Committee of IonQ’s Board. “Unde

Sealing System launches: XIO – Intelligent Farming26.4.2024 12:17:00 CEST | Press release

XIO – Intelligent Farming, specializes in logistics systems for insect protein production. XIO is a new business unit within Sealing System A/S, one of the leading providers of automated end-of-line packaging lines in Scandinavia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240426832303/en/ Robotic solution handling Black Soldier Fly Larvae (Photo: Business Wire) “At Sealing System A/S, we believe that practical innovation is the engine of real-world change. With the establishment of, XIO - Intelligent Farming, we are setting new industry standards, emphasizing the importance of intralogistics in the field of insect protein production, and proudly leading the way.” Ole Jensen CEO, Sealing System A/S XIO – Intelligent Farming provides solutions serving various aspects of the insect production, including fully automatic logistics systems, comprehensive data tracking, transfer trolleys and shuttles, as well as robot systems

Tecnotree Achieves Strong Q1 2024 Results with Sustained Revenue Growth and Enhanced Profitability26.4.2024 10:46:00 CEST | Press release

Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced its financial results for the first quarter of 2024, demonstrating solid growth with a 4.7% increase in revenue. The company maintained its momentum in driving global sales of its digital platform, in the first quarter of 2024, completing many AIML and digital transformations to key customers, resulting in a significant increase in revenue. The growth was primarily driven by new wins in the LATAM region, while EMEA and APAC regions remain growing markets for the digital platform. Key Q1 Highlights of the financial results: Net sales increased 4.7% to EUR 16.3 (15.5) million. Operating results increased by 22.3% to EUR 4.4 (3.6) million. Earnings per share EUR 0.01 (0.01). Order book at the end of the period increased by 10.3% to EUR 74.8 (67.8) million. Tecnotree achieved several notable milestones in the first quarter. The company solidified its position as a trusted par

HiddenA line styled icon from Orion Icon Library.Eye